Last reviewed · How we verify
Serevent
At a glance
| Generic name | Serevent |
|---|---|
| Also known as | LABA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Target | Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Adjunct Therapy to Achieve Long-term Asthma Control
- Allergic asthma
- Bronchospasm Prevention with COPD
- COPD Associated with Chronic Bronchitis
- Exercise-Induced Bronchospasm Prevention
- Non-allergic asthma
- Pulmonary emphysema
Common side effects
- Headache
- Headache
- Pharyngitis
- Nasal/sinus congestion, pallor
- Tracheitis/bronchitis
- Influenza
- Rhinitis
- Asthma
- Ear signs and symptoms
- Skin rashes
- Urticaria
- Nausea
Serious adverse events
- Asthma-related death
- Asthma-related hospitalization
- Elevation of hepatic enzymes
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- ANTES B+ Clinical Trial (PHASE4)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Serevent CI brief — competitive landscape report
- Serevent updates RSS · CI watch RSS
- Fundacio Privada Mon Clinic Barcelona portfolio CI